Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones

Muhammad Malik, Arkady Mustaev, Heidi A. Schwanz, Gan Luan, Nirali Shah, Lisa M. Oppegard, Ernane C. De Souza, Hiroshi Hiasa, Xilin Zhao, Robert J. Kerns, Karl Drlica

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Fluoroquinolones form drug-topoisomerase-DNA complexes that rapidly block transcription and replication. Crystallographic and biochemical studies show that quinolone binding involves a water/metal-ion bridge between the quinolone C3-C4 keto-acid and amino acids in helix-4 of the target proteins, GyrA (gyrase) and ParC (topoisomerase IV). A recent cross-linking study revealed a second drug-binding mode in which the other end of the quinolone, the C7 ring system, interacts with GyrA. We report that addition of a dinitrophenyl (DNP) moiety to the C7 end of ciprofloxacin (Cip-DNP) reduced protection due to resistance substitutions in Escherichia coli GyrA helix-4, consistent with the existence of a second drug-binding mode not evident in X-ray structures of drug-topoisomerase-DNA complexes. Several other C7 aryl fluoroquinolones behaved in a similar manner with particular GyrA mutants. Treatment of E. coli cultures with Cip-DNP selectively enriched an uncommon variant, GyrA-A119E, a change that may impede binding of the dinitrophenyl group at or near the GyrA-GyrA interface. Collectively the data support the existence of a secondary quinolone-binding mode in which the quinolone C7 ring system interacts with GyrA; the data also identify C7 aryl derivatives as a new way to obtain fluoroquinolones that overcome existing GyrA-mediated quinolone resistance.

Original languageEnglish (US)
Pages (from-to)3304-3316
Number of pages13
JournalNucleic acids research
Volume44
Issue number7
DOIs
StatePublished - Mar 16 2016

Fingerprint

Quinolones
Fluoroquinolones
DNA Topoisomerase IV
Type I DNA Topoisomerase
Pharmaceutical Preparations
Escherichia coli
Keto Acids
Ciprofloxacin
Metals
X-Rays
Ions
Amino Acids
Water

Cite this

Malik, M., Mustaev, A., Schwanz, H. A., Luan, G., Shah, N., Oppegard, L. M., ... Drlica, K. (2016). Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. Nucleic acids research, 44(7), 3304-3316. https://doi.org/10.1093/nar/gkw161

Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. / Malik, Muhammad; Mustaev, Arkady; Schwanz, Heidi A.; Luan, Gan; Shah, Nirali; Oppegard, Lisa M.; De Souza, Ernane C.; Hiasa, Hiroshi; Zhao, Xilin; Kerns, Robert J.; Drlica, Karl.

In: Nucleic acids research, Vol. 44, No. 7, 16.03.2016, p. 3304-3316.

Research output: Contribution to journalArticle

Malik, M, Mustaev, A, Schwanz, HA, Luan, G, Shah, N, Oppegard, LM, De Souza, EC, Hiasa, H, Zhao, X, Kerns, RJ & Drlica, K 2016, 'Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones', Nucleic acids research, vol. 44, no. 7, pp. 3304-3316. https://doi.org/10.1093/nar/gkw161
Malik M, Mustaev A, Schwanz HA, Luan G, Shah N, Oppegard LM et al. Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. Nucleic acids research. 2016 Mar 16;44(7):3304-3316. https://doi.org/10.1093/nar/gkw161
Malik, Muhammad ; Mustaev, Arkady ; Schwanz, Heidi A. ; Luan, Gan ; Shah, Nirali ; Oppegard, Lisa M. ; De Souza, Ernane C. ; Hiasa, Hiroshi ; Zhao, Xilin ; Kerns, Robert J. ; Drlica, Karl. / Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. In: Nucleic acids research. 2016 ; Vol. 44, No. 7. pp. 3304-3316.
@article{3aed69e67bcc4dbe99083b392cf024b7,
title = "Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones",
abstract = "Fluoroquinolones form drug-topoisomerase-DNA complexes that rapidly block transcription and replication. Crystallographic and biochemical studies show that quinolone binding involves a water/metal-ion bridge between the quinolone C3-C4 keto-acid and amino acids in helix-4 of the target proteins, GyrA (gyrase) and ParC (topoisomerase IV). A recent cross-linking study revealed a second drug-binding mode in which the other end of the quinolone, the C7 ring system, interacts with GyrA. We report that addition of a dinitrophenyl (DNP) moiety to the C7 end of ciprofloxacin (Cip-DNP) reduced protection due to resistance substitutions in Escherichia coli GyrA helix-4, consistent with the existence of a second drug-binding mode not evident in X-ray structures of drug-topoisomerase-DNA complexes. Several other C7 aryl fluoroquinolones behaved in a similar manner with particular GyrA mutants. Treatment of E. coli cultures with Cip-DNP selectively enriched an uncommon variant, GyrA-A119E, a change that may impede binding of the dinitrophenyl group at or near the GyrA-GyrA interface. Collectively the data support the existence of a secondary quinolone-binding mode in which the quinolone C7 ring system interacts with GyrA; the data also identify C7 aryl derivatives as a new way to obtain fluoroquinolones that overcome existing GyrA-mediated quinolone resistance.",
author = "Muhammad Malik and Arkady Mustaev and Schwanz, {Heidi A.} and Gan Luan and Nirali Shah and Oppegard, {Lisa M.} and {De Souza}, {Ernane C.} and Hiroshi Hiasa and Xilin Zhao and Kerns, {Robert J.} and Karl Drlica",
year = "2016",
month = "3",
day = "16",
doi = "10.1093/nar/gkw161",
language = "English (US)",
volume = "44",
pages = "3304--3316",
journal = "Nucleic Acids Research",
issn = "0305-1048",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones

AU - Malik, Muhammad

AU - Mustaev, Arkady

AU - Schwanz, Heidi A.

AU - Luan, Gan

AU - Shah, Nirali

AU - Oppegard, Lisa M.

AU - De Souza, Ernane C.

AU - Hiasa, Hiroshi

AU - Zhao, Xilin

AU - Kerns, Robert J.

AU - Drlica, Karl

PY - 2016/3/16

Y1 - 2016/3/16

N2 - Fluoroquinolones form drug-topoisomerase-DNA complexes that rapidly block transcription and replication. Crystallographic and biochemical studies show that quinolone binding involves a water/metal-ion bridge between the quinolone C3-C4 keto-acid and amino acids in helix-4 of the target proteins, GyrA (gyrase) and ParC (topoisomerase IV). A recent cross-linking study revealed a second drug-binding mode in which the other end of the quinolone, the C7 ring system, interacts with GyrA. We report that addition of a dinitrophenyl (DNP) moiety to the C7 end of ciprofloxacin (Cip-DNP) reduced protection due to resistance substitutions in Escherichia coli GyrA helix-4, consistent with the existence of a second drug-binding mode not evident in X-ray structures of drug-topoisomerase-DNA complexes. Several other C7 aryl fluoroquinolones behaved in a similar manner with particular GyrA mutants. Treatment of E. coli cultures with Cip-DNP selectively enriched an uncommon variant, GyrA-A119E, a change that may impede binding of the dinitrophenyl group at or near the GyrA-GyrA interface. Collectively the data support the existence of a secondary quinolone-binding mode in which the quinolone C7 ring system interacts with GyrA; the data also identify C7 aryl derivatives as a new way to obtain fluoroquinolones that overcome existing GyrA-mediated quinolone resistance.

AB - Fluoroquinolones form drug-topoisomerase-DNA complexes that rapidly block transcription and replication. Crystallographic and biochemical studies show that quinolone binding involves a water/metal-ion bridge between the quinolone C3-C4 keto-acid and amino acids in helix-4 of the target proteins, GyrA (gyrase) and ParC (topoisomerase IV). A recent cross-linking study revealed a second drug-binding mode in which the other end of the quinolone, the C7 ring system, interacts with GyrA. We report that addition of a dinitrophenyl (DNP) moiety to the C7 end of ciprofloxacin (Cip-DNP) reduced protection due to resistance substitutions in Escherichia coli GyrA helix-4, consistent with the existence of a second drug-binding mode not evident in X-ray structures of drug-topoisomerase-DNA complexes. Several other C7 aryl fluoroquinolones behaved in a similar manner with particular GyrA mutants. Treatment of E. coli cultures with Cip-DNP selectively enriched an uncommon variant, GyrA-A119E, a change that may impede binding of the dinitrophenyl group at or near the GyrA-GyrA interface. Collectively the data support the existence of a secondary quinolone-binding mode in which the quinolone C7 ring system interacts with GyrA; the data also identify C7 aryl derivatives as a new way to obtain fluoroquinolones that overcome existing GyrA-mediated quinolone resistance.

UR - http://www.scopus.com/inward/record.url?scp=84965139780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965139780&partnerID=8YFLogxK

U2 - 10.1093/nar/gkw161

DO - 10.1093/nar/gkw161

M3 - Article

VL - 44

SP - 3304

EP - 3316

JO - Nucleic Acids Research

JF - Nucleic Acids Research

SN - 0305-1048

IS - 7

ER -